Featured Research

from universities, journals, and other organizations

Novel MS Drug Shows Promise In Two Lethal Leukemias

Date:
August 28, 2007
Source:
Ohio State University
Summary:
A new study suggests that an experimental drug being tested for the treatment of multiple sclerosis and to prevent organ rejection might also help people with certain deadly forms of chronic and acute leukemia. The laboratory and animal study focused on the drug, called fingolimod. Researchers said it might help patients with advanced chronic myelogenous leukemia or acute lymphocytic leukemia, and whose cancer cells show a particular genetic change called the Philadelphia chromosome.

A new study suggests that an experimental drug being tested for the treatment of multiple sclerosis and to prevent organ rejection might also help people with certain deadly forms of chronic and acute leukemia.

Related Articles


The laboratory and animal study focused on the drug, called fingolimod. Researchers said it might help patients with advanced chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL), and whose cancer cells show a particular genetic change called the Philadelphia chromosome.

The study found that the drug prevented the development of these cancers in mouse models, as well as killing laboratory-grown human CML and ALL cells.

Although the findings must be verified in humans through a future clinical trial, the new research also suggests that the drug might help patients with these leukemias who are resistant to imatinib (Gleevec) and dasatinib (Sprycel), two important current drugs for treating CML and those cases of ALL with the Philadelphia chromosome.

Presently, fingolimod is in advanced clinical-trials testing for the treatment of relapsing multiple sclerosis, and to prevent organ rejection following kidney transplantation.

“This novel agent represents a promising new strategy for treating CML that is resistant to imatinib and related targeted agents,” says coauthor Guido Marcucci, associate professor of internal medicine and an oncologist who specializes in leukemia drug development at Ohio State's James Cancer Hospital and Solove Research Institute.

“These findings also suggest that it will be an important contribution to a new therapeutic approach to CML that considers combinations of molecular targeting compounds.”

In leukemic cells, the drug works by reactivating a protein called PP2A, which normally helps protect cells from becoming cancerous. The protein then causes the cells to self-destruct through a process called apoptosis.

“This was true even in leukemic cells from patients that were resistant to imatinib or to dasatinib,” says principal investigator Danilo Perrotti, assistant professor of molecular virology, immunology and medical genetics.

The drug had no effect on normal cells or control mice, suggesting that it is likely to have minimal or no side effects in humans.

“If this is verified in future studies, it means that this drug might help patients who do not respond to other therapies,” Perrotti says

Nearly all of the 4,570 cases of CML expected this year, and about 20 percent of the expected 5,200 cases of ALL, have the Philadelphia chromosome. This chromosome change results in the production of an abnormal protein that causes these two malignancies.

This study tested the drug on cell lines that modeled these leukemias, and on cells from patients with advanced CML or with ALL and the Philadelphia chromosome, including those who were resistant to imatinib and dasatinib.

The animal studies used mice with the two forms of leukemia. Whereas most of the 39 untreated animals had died by four weeks, 90 percent of the 39 animals treated with the drug were alive after six months.

The study's findings, Perrotti says, “support the use of this PP2A activator as a novel therapeutic approach in these particular leukemias and, perhaps, in other cancers that involve the functional loss of PP2A activity.”

The new study, led by researchers with the Ohio State University Comprehensive Cancer Center, is published online Aug. 23 in the Journal of Clinical Investigation.

This work was supported in part by grants from the National Cancer Institute; the U.S. Army, Chronic Myelogenous Leukemia Research Program; the Leukemia Clinical Research Foundation; the Leukemia and Lymphoma Society; the D. Warren Brown Foundation; the American-Italian Cancer Foundation; the Italian Association for Cancer Research and the Italian Ministry of Health; and by Fonds de la Recherche en Sante du Quebec.


Story Source:

The above story is based on materials provided by Ohio State University. Note: Materials may be edited for content and length.


Cite This Page:

Ohio State University. "Novel MS Drug Shows Promise In Two Lethal Leukemias." ScienceDaily. ScienceDaily, 28 August 2007. <www.sciencedaily.com/releases/2007/08/070828110642.htm>.
Ohio State University. (2007, August 28). Novel MS Drug Shows Promise In Two Lethal Leukemias. ScienceDaily. Retrieved November 26, 2014 from www.sciencedaily.com/releases/2007/08/070828110642.htm
Ohio State University. "Novel MS Drug Shows Promise In Two Lethal Leukemias." ScienceDaily. www.sciencedaily.com/releases/2007/08/070828110642.htm (accessed November 26, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, November 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins